全球人源化小鼠模型市场规模（按类型、应用、最终用户、地区、范围和预测）

人源化小鼠模型的市场规模及预测

人源化小鼠模型市场规模预计在2024 年将达到1.2477 亿美元，到2031 年将达到2.4226 亿美元，在2024-2031 年预测期内的复合年增长率为9.54%。 。人源化小鼠模型是一种经过基因编辑的实验室小鼠，包含人类基因、器官甚至免疫系统。科学家培育小鼠是为了更好地瞭解人类疾病并在体内测试潜在的治疗方法。这些老鼠具有类似人类的特征，因此比传统老鼠更能有效复製疾病在人体中的进展。它们是生物医学研究中必不可少的工具，具有广泛的应用，有助于瞭解人类生物学和疾病。这些小鼠经过基因改造，携带人类基因、组织和细胞，使其成为研究人类特定体内生物过程的理想选择。人源化小鼠模型主要用于药物研究和测试。

人源化小鼠模型预计将在未来的生物医学研究中发挥重要作用，特别是在药物开发、免疫学和个人化医疗方面。人源化小鼠模型经过基因改造，拥有人类基因、器官和免疫细胞，是研究人类疾病和在受控环境中测试潜在治疗方法的理想选择。

人源化小鼠模型的全球市场动态

主要市场推动因素

个人化医疗的进展：

个人化医疗的兴起是人源化小鼠模型业务的主要动力。个人化医疗寻求根据个别患者的基因组成客製化治疗方案，人性化小鼠模型在这方面非常有用。这些模型经过设计，具有类似人类的免疫系统和其他人类基因，使研究人员能够研究人类特有的疾病以及不同的治疗方法在不同遗传背景下的作用。

慢性病盛行率增加：

慢性病的发生率不断上升，推动了对人性化小鼠模型的需求。这些模型比标准动物模型更准确地描述人类疾病状态，而标准动物模型通常无法充分模拟人类生理学。例如，在癌症研究中，可以将人类肿瘤植入人源化小鼠，以便在受控环境下研究肿瘤的生长、转移和对药物的反应。

基因工程的技术进步：

基因工程技术的发展大大提高了人源化小鼠的生产和实用性。CRISPR/Cas9 技术使基因编辑变得更容易、更精确，使研究人员能够开发出更接近人类生物学的模型。这些技术进步使得更为复杂和精确的人源化小鼠的开发成为可能，这对于研究复杂的人类疾病、药物反应和免疫系统功能至关重要。

主要课题

基因工程的复杂性

开发人性化小鼠模型是一个耗时且复杂的过程。这些模型需要将人类基因、器官和免疫细胞引入小鼠体内，这需要复杂的基因工程程序。将人类元素插入小鼠基因组并确保其正常运作的过程非常困难。

寿命有限和繁殖问题：

人源化小鼠有较大的问题，包括寿命短、繁殖困难。人类基因和细胞的整合往往会导致免疫系统减弱和其他健康问题，使人们更容易生病并缩短寿命。

人性化不完全

另一个问题是人源化小鼠模型并不总是完全代表人类生物学。儘管它们可以模仿人类免疫反应和疾病过程的特征，但它们本质上仍然属于小鼠，在复製人类生理学方面有其限制。

主要趋势：

基因工程的进展

一个值得注意的趋势是，基因工程技术的重大进展使得建构更精确、更复杂的人源化小鼠模型成为可能。包括 CRISPR-Cas9 在内的基因编辑技术现在允许科学家精确修改小鼠基因组，以包括人类基因、细胞、器官甚至整个人类免疫系统。

在免疫肿瘤学研究的应用日益广泛

人源化小鼠模型在免疫肿瘤学中变得越来越重要，该领域研究如何利用免疫系统对抗癌症。这些模型对于评估免疫疗法（增强人体对癌细胞的免疫反应的药物）的有效性特别有用。

扩大传染病研究

另一个趋势是人源化小鼠模型在传染病研究中的应用越来越多，特别是在研究人类特异性传染病，如爱滋病毒、肝炎以及最近的 COVID-19。这些模型对于瞭解病毒如何与人类细胞和免疫系统相互作用非常重要，因为典型的动物模型很难模拟这些相互作用。

目录

第1章 全球人源化小鼠模型市场介绍

• 市场概况
• 调查范围
• 先决条件

第 2 章执行摘要

第3章 VERIFIED MARKET RESEARCH研究方法

• 数据挖掘
• 验证
• 一次资料
• 数据源列表

第4章 全球人源化小鼠模型市场展望

• 概述
• 市场动态
  • 促进因素
  • 阻碍因素
  • 机会
• 波特的五力模型
• 价值链分析

第5章全球人源化小鼠模型市场依类型划分

• 概述
• 基因人源化小鼠模型
• 基于细胞的人源化小鼠模型
  • CD34人类源化小鼠模型（Hu-CD34）
  • PBMC人源化小鼠模型
  • BLT人源化小鼠模型

第6章全球人源化小鼠模型市场（依应用）

• 概述
• 肿瘤学
• 免疫学/传染病
• 神经科学
• 毒理学
• 造血
• 其他

第7章全球人源化小鼠模型市场依最终用户划分

• 概述
• 製药和生物技术公司
• 合同研究所
• 学术/研究机构

第8章全球人源化小鼠模型市场（按地区）

• 概述
• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 亚太其他地区
• 世界其他地区
  • 拉丁美洲
  • 中东/非洲

第9章全球人源化小鼠模型市场竞争格局

• 概述
• 企业市占率
• 供应商情况
• 主要发展策略

第10章 公司简介

• The Jackson Laboratory
• Taconic Biosciences, Inc.
• Horizon Discovery Group PLC
• Genoway S.A.
• Harbour Antibodies Bv（A Subsidiary of Harbour Biomed）
• Humurine Technologies
• Vitalstar Biotechnology Co., Ltd.
• Ingenious Targeting Laboratory
• Axenis S.A.S
• Trans Genic, Inc.

第 11 章 附录

• 相关报导

Humanized Mouse Model Market Size And Forecast

Humanized Mouse Model Market size was valued at USD 124.77 Million in 2024 and is projected to reach USD 242.26 Million by 2031 , growing at a CAGR of 9.54% from 2024 to 2031. A humanized mouse model is a sort of laboratory mouse that has been genetically edited to contain human genes, organs, and even an immune system. Scientists develop these mice to better understand human ailments and test potential remedies in a living organism. Since these mice have human-like traits, they can more effectively replicate how a sickness might progress in a human body than conventional mice. These are essential tools in biomedical research, with a wide range of applications that help us understand human biology and illness. These mice are genetically modified to carry human genes, tissues, or cells, making them ideal for investigating human-specific biological processes in living organisms. Humanized mouse models are mostly used in medication research and testing.

Humanized mouse models are predicted to play an important role in future biomedical research, particularly in drug development, immunology, and personalized medicine. Humanized mouse models are genetically modified to carry human genes, organs, or immune cells making them ideal for studying human diseases and testing potential treatments in a controlled setting.

Global Humanized Mouse Model Market Dynamics

The key market dynamics that are shaping the global humanized mouse model market include:

Key Market Drivers:

Advances in Personalized Medicine:

The rise of personalized medicine is a major driver of the humanized mouse model business. Personalized medicine seeks to customize therapies for individual patients based on their genetic makeup, and humanized mouse models are extremely useful in this setting. These models which are designed to have human-like immune systems or other human genes, enable researchers to investigate human-specific diseases and explore how different treatments might function on diverse genetic backgrounds.

Increasing Prevalence of Chronic Diseases:

Chronic disease prevalence is increasing which is fuelling demand for humanized mouse models. These models offer a more accurate picture of human disease states than standard animal models which frequently fail to properly imitate human physiology. For example, in cancer research, humanized mice can be implanted with human tumors allowing scientists to examine tumor growth, metastasis, and response to medicines in a controlled setting.

Technological Advancements in Genetic Engineering:

Technological developments in genetic engineering have greatly improved the generation and utility of humanized mouse models. CRISPR/Cas9 techniques have made gene editing easier and more precise allowing researchers to develop models that closely match human biology. These technical advancements enable the development of more sophisticated and precise humanized mice which are critical for researching complex human diseases, medication reactions, and immune system functioning.

Key Challenges:

Complexity in Genetic Engineering

: Developing humanized mouse models is a time-consuming and complex procedure. These models necessitate the introduction of human genes, organs, or immune cells into mice which requires advanced genetic engineering procedures. The procedure of inserting human elements into the mouse genome and ensuring that they work properly is difficult.

Limited Lifespan and Reproduction Issues:

Humanized mice have a short lifetime and have difficulty reproducing which presents a big problem. The integration of human genes or cells frequently results in mice with weakened immune systems or other health issues rendering them more susceptible to disease and shortening their lifespan.

Incomplete Humanization

: Another issue is that humanized mouse models are frequently not completely representative of human biology. While they can mimic some features of human immune responses or disease processes, they are still fundamentally mice with limitations in their ability to duplicate human physiology.

Key Trends:

Advances in Genetic Engineering

: One noteworthy trend is the substantial advancement of genetic engineering techniques making it possible to construct more precise and complex humanized mouse models. CRISPR-Cas9 and other gene-editing technologies enable scientists to accurately alter mouse genomes to include human genes, cells, organs, and even entire human immune systems.

Increasing Use in Immuno-Oncology Research

. Humanized mouse models are becoming increasingly significant in immuno-oncology which studies how the immune system might be used to combat cancer. These models are especially useful for assessing the efficacy of immunotherapies which are medicines that increase the body's immunological response to cancer cells.

Expansion in Infectious Disease Research

: Another trend is the increased use of humanized mouse models in infectious disease research, particularly for researching human-specific infections such as HIV, hepatitis, and, most recently, COVID-19. These models are critical for learning how viruses interact with human cells and immune systems which is challenging to mimic using typical animal models.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Humanized Mouse Model Market Regional Analysis

Here is a more detailed regional analysis of the global humanized mouse model market:

North America:

North America dominates the humanized mouse model market owing to its strong research infrastructure and large investments in biomedical research. This supremacy is anticipated to persist in the next years, thanks to several major drivers. The first key driver of the humanized mouse model market in North America is the rising prevalence of chronic illnesses and cancer.

According to the Centers for Disease Control and Prevention (CDC), by 2021, 6 out of 10 adults in the United States will have a chronic disease with 4 out of 10 having two or more. Cancer, in particular, remains a major problem with the National Cancer Institute predicting 1,958,310 new cases in the United States by 2023.

The National Institutes of Health (NIH), the world's largest public supporter of biomedical research has a USD 45 Billion budget for fiscal year 2023 including a considerable amount dedicated to animal model research. Furthermore, the US Food and Drug Administration (FDA) has advocated for the use of humanized mouse models in preclinical investigations to better the translation of research findings into human applications.

Asia Pacific:

The Asia Pacific region is experiencing the quickest growth in the humanized mouse model market owing to significant advances in biomedical research and increased investments in healthcare infrastructure. This fast expansion is fueled by the region's booming pharmaceutical and biotechnology sectors as well as a growing emphasis on individualized medicine.

Chronic diseases such as cancer and autoimmune disorders have become increasingly common in the region. According to the World Health Organization, cancer is the biggest cause of death in Asia Pacific accounting for an estimated 8.8 million new cases and 5.5 million deaths in 2018. This has resulted in a greater desire for more efficient drug research and development processes with humanized mouse models playing an important role.

Asia Pacific's pharmaceutical and biotechnology industry have expanded rapidly. According to the Japan Pharmaceutical Manufacturers Association, the Japanese pharmaceutical market was valued at around 10.7 trillion yen (USD 98 Billion) in 2020 making it the world's third-largest market. This expansion has increased the demand for improved preclinical research tools, such as humanized mouse models.

Global Humanized Mouse Model Market: Segmentation Analysis

The Global Humanized Mouse Model Market is segmented based on Type, Application, End-User, and Geography.

Humanized Mouse Model Market, By Type

• Genetic Humanized Mouse Model
• Cell-Based Humanized Mouse Model
• CD34 Humanized Mouse Model (Hu-CD34)
• PBMC Humanized Mouse Model
• BLT Humanized Mouse Model

Based on the Type, the Global Humanized Mouse Model Market is bifurcated into Genetic Humanized Mouse Model, Cell-Based Humanized Mouse Model, CD34 Humanized Mouse Model (Hu-CD34), PBMC Humanized Mouse Model, and BLT Humanized Mouse Model. The genetic humanized mouse model is currently dominant in the global humanized mouse model market. This dominance is due to the model's advanced capability to replicate human-specific genes within the mouse genome providing researchers with a powerful tool to study human diseases, particularly in genetics and drug development. These models are essential for understanding gene function, and disease mechanisms, and for testing new therapies in a more human-relevant context.

Humanized Mouse Model Market, By Application

• Immunology and Infectious Diseases
• Neuroscience
• Oncology
• Haematopoiesis
• Toxicology
• Others

Based on the Application, the Global Humanized Mouse Model Market is bifurcated into Immunology and Infectious Diseases, Neuroscience, Oncology, Haematopoiesis, Toxicology, and Others. Oncology is the dominant application in the global humanized mouse model market. This dominance is driven by the critical role these models play in cancer research, particularly in the development of immunotherapies. Humanized mouse models are invaluable for studying human tumor growth and testing new cancer treatments, especially those targeting the immune system.

Humanized Mouse Model Market, By End-User

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic & Research Institutions

Based on the End-User, the Global Humanized Mouse Model Market is bifurcated into Pharmaceutical & Biotechnology Companies, Contract Research Organizations, and Academic & Research Institutions. Pharmaceutical & biotechnology companies are the dominant end users in the global humanized mouse model market. This dominance is driven by their extensive use of these models for drug discovery, development, and testing. Humanized mouse models are crucial for evaluating the efficacy and safety of new drugs, particularly those targeting complex human diseases and conditions. These companies rely on humanized mice to simulate human biological responses and predict how new therapies will perform in clinical trials.

Humanized Mouse Model Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Global Humanized Mouse Model Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America is the dominant region in the global humanized mouse model market. This dominance is due to the region's advanced research infrastructure, high level of investment in biomedical research, and strong presence of major biotechnology and pharmaceutical companies. North America, particularly the United States leads in the development and adoption of innovative research technologies including humanized mouse models.

Key Players

• The "Global Humanized Mouse Model Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• The Jackson Laboratory, Taconic Biosciences, Inc., Horizon Discovery Group PLC, Genoway S.A., Harbour Antibodies Bv (A Subsidiary of Harbour Biomed), Humurine Technologies, Vitalstar Biotechnology Co., Ltd., Ingenious Targeting Laboratory, Axenis S.A.S, Trans Genic, Inc., Champions Oncology, Inc., Crown Bioscience, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Humanized Mouse Model Market Key Developments

• In January 2020, Taconic Biosciences, a global pioneer in developing drug discovery animal models, established a new model generation facility in Leverkusen, Germany. This complex, which replaces the previous Taconic facility in Cologne, Germany, houses model generation services.
• In January 2021, Champions Cancer, Inc., a leading worldwide cancer technology business that is redefining drug discovery and development with data-driven research techniques, today announced the expansion of their Lumin Bioinformatics SaaS program.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL HUMANIZED MOUSE MODEL MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL HUMANIZED MOUSE MODEL MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL HUMANIZED MOUSE MODEL MARKET, BY TYPE

• 5.1 Overview
• 5.2 Genetic Humanized Mouse Model
• 5.3 Cell-Based Humanized Mouse Model
  • 5.3.1 CD34 Humanized Mouse Model (Hu-CD34)
  • 5.3.2 PBMC Humanized Mouse Model
  • 5.3.3 BLT Humanized Mouse Model

6 GLOBAL HUMANIZED MOUSE MODEL MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Oncology
• 6.3 Immunology and infectious diseases
• 6.4 Neurosciences
• 6.5 Toxicology
• 6.6 Hematopoiesis
• 6.7 Others

7 GLOBAL HUMANIZED MOUSE MODEL MARKET, BY END-USER

• 7.1 Overview
• 7.2 Pharmaceutical and Biotechnology Companies
• 7.3 Contract Research Organizations
• 7.4 Academic and Research Institutions

8 GLOBAL HUMANIZED MOUSE MODEL MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East And Africa

9 GLOBAL HUMANIZED MOUSE MODEL MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Share
• 9.3 Vendor Landscape
• 9.4 Key Development Strategies

10 COMPANY PROFILES

• 10.1 The Jackson Laboratory
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Taconic Biosciences, Inc.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Horizon Discovery Group PLC
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Genoway S.A.
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Harbour Antibodies Bv (A Subsidiary of Harbour Biomed)
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Humurine Technologies
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Vitalstar Biotechnology Co., Ltd.
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Ingenious Targeting Laboratory
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Axenis S.A.S
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Trans Genic, Inc.
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Reports